270 Littlefield Avenue,
South San Francisco, California 94080
KAI Pharmaceuticals is a life science company based in South San Francisco. KAI's lead product candidate KAI-4169 is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. KAI has previously reported compelling Phase 2a clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.
KAI Pharmaceuticals was acquired by Amgen on April 10, 2012.
Join Mergr to view all 119 acquisitions of life science companies in 2012, including 19 acquisitions by private equity firms, and 100 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 18 in number of deals in 2012. The largest life science acquisition in 2012 was Amylin Pharmaceuticals - which was acquired by Bristol-Myers Squibb for $5.3B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like KAI Pharmaceuticals.
No obligation. Cancel anytime.